| Date | Time | Source | Headline | Symbol | Company |
| 09/09/2024 | 6:30AM | GlobeNewswire Inc. | Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop | NASDAQ:OCGN | Ocugen Inc |
| 09/05/2024 | 7:00AM | GlobeNewswire Inc. | Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit | NASDAQ:OCGN | Ocugen Inc |
| 09/03/2024 | 7:30AM | GlobeNewswire Inc. | Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference | NASDAQ:OCGN | Ocugen Inc |
| 08/28/2024 | 6:30AM | GlobeNewswire Inc. | Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy | NASDAQ:OCGN | Ocugen Inc |
| 08/26/2024 | 7:02AM | GlobeNewswire Inc. | Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication | NASDAQ:OCGN | Ocugen Inc |
| 08/20/2024 | 9:00AM | PR Newswire (US) | Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading | NASDAQ:OCGN | Ocugen Inc |
| 08/16/2024 | 4:16PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:OCGN | Ocugen Inc |
| 08/13/2024 | 8:00AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:OCGN | Ocugen Inc |
| 08/08/2024 | 1:03PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:OCGN | Ocugen Inc |
| 08/08/2024 | 6:45AM | GlobeNewswire Inc. | Ocugen Provides Business Update with Second Quarter 2024 Financial Results | NASDAQ:OCGN | Ocugen Inc |
| 08/08/2024 | 6:06AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:OCGN | Ocugen Inc |
| 08/05/2024 | 7:18AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:OCGN | Ocugen Inc |
| 08/05/2024 | 6:30AM | GlobeNewswire Inc. | Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa | NASDAQ:OCGN | Ocugen Inc |
| 08/02/2024 | 3:22PM | GlobeNewswire Inc. | Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock | NASDAQ:OCGN | Ocugen Inc |
| 08/01/2024 | 9:18AM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:OCGN | Ocugen Inc |
| 08/01/2024 | 9:16AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:OCGN | Ocugen Inc |
| 07/31/2024 | 9:15PM | GlobeNewswire Inc. | Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock | NASDAQ:OCGN | Ocugen Inc |
| 07/31/2024 | 4:16PM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:OCGN | Ocugen Inc |
| 07/31/2024 | 4:15PM | GlobeNewswire Inc. | Ocugen, Inc. Announces Proposed Public Offering of Common Stock | NASDAQ:OCGN | Ocugen Inc |
| 07/29/2024 | 7:02AM | GlobeNewswire Inc. | Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results | NASDAQ:OCGN | Ocugen Inc |
| 07/25/2024 | 6:30AM | GlobeNewswire Inc. | Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy | NASDAQ:OCGN | Ocugen Inc |
| 07/08/2024 | 4:31PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:OCGN | Ocugen Inc |
| 06/21/2024 | 7:00AM | GlobeNewswire Inc. | Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease | NASDAQ:OCGN | Ocugen Inc |
| 06/20/2024 | 6:30AM | GlobeNewswire Inc. | Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication | NASDAQ:OCGN | Ocugen Inc |
| 06/18/2024 | 4:29PM | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:OCGN | Ocugen Inc |
| 06/06/2024 | 4:31PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:OCGN | Ocugen Inc |
| 05/31/2024 | 8:36AM | GlobeNewswire Inc. | Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy | NASDAQ:OCGN | Ocugen Inc |
| 05/29/2024 | 7:15AM | GlobeNewswire Inc. | Ocugen to Present at BIO International Convention 2024 | NASDAQ:OCGN | Ocugen Inc |
| 05/28/2024 | 4:05PM | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:OCGN | Ocugen Inc |
| 05/28/2024 | 7:02AM | GlobeNewswire Inc. | Ocugen Set to Join Russell 3000® Index Effective June 28, 2024 | NASDAQ:OCGN | Ocugen Inc |